Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21819272 | 0.92 | MAOB (0.43) | MAOBCNR1MAOAF10 | |
| SCHEMBL28584086 | 0.83 | CNR1 (0.42) | MAOBCNR1MAOACNR2CHRNB2 | |
| SCHEMBL21819339 | 0.83 | ATF4 (0.47) | MAOBCNR1MAOACHRNB2CHRNA7 | |
| SCHEMBL21882372 | 0.80 | CNR1 (0.48) | MAOBCNR1CNR2SMN1; SMN2 | |
| SCHEMBL21882075 | 0.80 | ATF4 (0.56) | CNR1F10CNR2 | |
| SCHEMBL21882367 | 0.76 | TRPA1 (0.48) | CNR1CNR2 | |
| SCHEMBL29437004 | 0.76 | TRPA1 (0.48) | CNR1CNR2 | |
| Trifluoroacetic Acid SCHEMBL21819604 | 0.74 | ATF4 (0.55) | CNR1CNR2 | |
| Trifluoroacetic Acid SCHEMBL21819626 | 0.73 | CNR1 (0.42) | MAOBCNR1MAOA | |
| SCHEMBL21819472 | 0.72 | STS (0.52) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | MAOB 2567/4885CNR1 2950/4885MAOA 3161/4885 |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | MAOB 2567/4885CNR1 2950/4885MAOA 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.